You just read:

Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I

News provided by

Sangamo Therapeutics, Inc.

Feb 27, 2017, 08:00 ET